Celladon Corp., a developer of treatments for cardiovascular diseases, has closed on $43 million in new capital. Pfizer Venture Investments led the round, which included investment from new backers Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners. All previous investors participated in this round, including Enterprise Partners Venture Capital, Johnson [...]
You are browsing the archive for GBS Venture Partners - peHUB.
AirXpanders, a company developing technology to address unmet needs for patients who require tissue expansion for breast reconstruction surgery, has secured $10 million in Series D financing. The round includes $7 million from new investor Vivo Ventures and $3 million from existing investors GBS Venture Partners, Prolog Ventures, Heron Capital and WTI. PRESS RELEASE AirXpanders [...]
Uptake Medical has closed a Series C funding round. The round was led by Singapore-based Crescent Point Group, with existing investors, Maverick Capital, ONSET Ventures, GBS Venture Partners, WRF Capital, Arboretum Ventures and Affinity Capital, making additional investments. Uptake Medical is focused on the development and commercialization of innovative, non-surgical treatments for lung diseases. PRESS [...]
Australia’s Spinifex Pharmaceuticals has closed its Series B round after adding an additional AU$6.25 million ($6.5 million) from GBS Venture Partners, Brandon Capital Partners, Uniseed Management and UniQuest. The total amount raised in the round was $19 million. The money will help fund the development of Spinifex’s pain management drug.
Palo Alto, Calif.-based Viveve announced today that Michael Krychman, M.D., has joined its scientific advisory board. Krychman is board-certified obstetrician and gynecologist. Viveve is a device company whose product is used in a non-surgical procedure that treats post-birth laxity of the vaginal introitus. Viveve has raised an undisclosed amount of Series A financing from GBS Venture Partners and 5AM [...]
San Diego-based CoDa Therapeutics Inc. has raised $19.2 million in a first closing of Series B financing. Existing shareholders Domain Associates, GBS Venture Partners and BioPacificVentures participated in the round. CoDa is a clinical-stage biopharmaceutical company working to develop drug therapies for wounds that do not heal properly, including venous leg and diabetic foot ulcers. The company will use the Series B financing for continued development.